Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 14/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.58 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.58 |
| ▸ | PRKACA | P17612 | 2/20 | 0.58 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.58 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.58 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.58 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.58 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.58 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.58 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.58 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 4/20 | 0.52 |
| ▸ | MAOB | P27338 | 4/20 | 0.52 |
| ▸ | PRKX | P51817 | 1/20 | 0.52 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.52 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.52 |
| ▸ | CCR2 | P41597 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4007501 | 0.92 | ROCK1 (0.58) | ROCK1ROCK2PRKCDPRKACAPRKG1 | |
| SCHEMBL8934763 | 0.91 | ROCK1 (0.60) | ROCK1ROCK2PRKCDPRKACAPRKG1 | |
| SCHEMBL8938641 | 0.90 | ROCK1 (0.54) | ROCK1ROCK2PRKCDPRKACAPRKG1 | |
| SCHEMBL4006061 | 0.90 | ROCK1 (0.56) | ROCK1ROCK2PRKCDPRKACAPRKG1 | |
| SCHEMBL4005889 | 0.89 | ROCK1 (0.61) | ROCK1ROCK2PRKCDPRKACAPRKG1 | |
| SCHEMBL8936219 | 0.88 | ROCK1 (0.53) | ROCK1ROCK2PRKCDPRKACAPRKG1 | |
| SCHEMBL8934869 | 0.88 | ROCK1 (0.54) | ROCK1ROCK2PRKCDPRKACAPRKG1 | |
| SCHEMBL8934812 | 0.88 | ROCK1 (0.58) | ROCK1ROCK2PRKCDPRKACAPRKG1 | |
| SCHEMBL8934871 | 0.88 | ROCK1 (0.58) | ROCK1ROCK2PRKCDPRKACAPRKG1 | |
| SCHEMBL8938636 | 0.87 | ROCK1 (0.53) | ROCK1ROCK2PRKCDPRKACAPRKG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963304-B2 | ISOQUINOLINE DERIVATIVES | MSD OSS BV (NL) | 2015-05-13 | — | — | EP | disclosed |
| EP-2385047-B1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI SA (FR) | 2013-05-29 | — | — | EP | disclosed |
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| EP-2385047-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI (FR) | 2011-11-09 | — | — | EP | disclosed |
| US-7618985-B2 | Isoquinoline derivatives | N.V. ORGANON (NL) | 2009-11-17 | — | — | US | disclosed |
| EP-1963304-B1 | ISOQUINOLINE DERIVATIVES | ORGANON NV (NL) | 2009-06-24 | — | — | EP | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
| EP-1963304-A1 | ISOQUINOLINE DERIVATIVES | N.V. Organon (NL) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007065916-A1 | ISOQUINOLINE DERIVATIVES | N.V. ORGANON (NL) | 2007-06-14 | — | — | WO | disclosed |
| US-20070135479-A1 | Isoquinoline derivatives | N.V. ORGANON (NL) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135479-A1 | Isoquinoline derivatives | ROCK1, ROCK2, RHOA | ROCK1 1/4885ROCK2 2/4885PRKCD 384/4885 |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | MYLK2, MYLK, RHOT2 | ROCK1 8/4885ROCK2 10/4885PRKCD 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.